ArticleClinical ophthalmology (Auckland, N.Z.)2011
Update on the role of genetics in the onset of age-related macular degeneration.
Article in Clinical ophthalmology (Auckland, N.Z.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis.PloS one · 2013Pooled it
- Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response-a scoping review.BMJ open ophthalmology · 2024Article
- Review
- Biomarkers as Predictive Factors of Anti-VEGF Response.Biomedicines · 2022Review
- Correlation between genetic and environmental risk factors for age-related macular degeneration in Brazilian patients.PloS one · 2022Article
- Article
- Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.BMC ophthalmology · 2021Article
- Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Observational
- MicroRNA Expression Analysis in Serum of Patients with Congenital Hemochromatosis and Age-Related Macular Degeneration (AMD).Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Recent advances in the management and understanding of macular degeneration.F1000Research · 2017Review
- Risk factors and biomarkers of age-related macular degeneration.Progress in retinal and eye research · 2016Review
- Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation).Mediators of inflammation · 2014Article
- Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks.Mediators of inflammation · 2013Review
- Article
- Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics.Molecular aspects of medicine · 2012Review
- Effect of the Gas6 c.834+7G>A polymorphism and the interaction of known risk factors on AMD pathogenesis in Hungarian patients.PloS one · 2012Article
- Mechanism of inflammation in age-related macular degeneration.Mediators of inflammation · 2012Review
- Biological effects of cigarette smoke in cultured human retinal pigment epithelial cells.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD), akin to other common age-related diseases, has a complex pathogenesis and arises from the interplay of genes, environmental factors, and personal characteristics. The past decade has seen very significant strides towards identification of those precise genetic variants associated with disease. That genes encoding proteins of the (alternative) complement pathway (CFH, C2, CFB, C3, CFI) are major players in etiology came as a surprise to many but has already lead to the development of therapies entering human clinical trials. Other genes replicated in many populations ARMS2, APOE, variants near TIMP3, and genes involved in lipid metabolism have also been implicated in disease pathogenesis. The genes discovered to date can be estimated to account for approximately 50% of the genetic variance of AMD and have been discovered by candidate gene approaches, pathway analysis, and latterly genome-wide association studies. Next generation sequencing modalities and meta-analysis techniques are being employed with the aim of identifying the remaining rarer but, perhaps, individually more significant sequence variations, linked to disease status. Complementary studies have also begun to utilize this genetic information to develop clinically useful algorithms to predict AMD risk and evaluate pharmacogenetics. In this article, contemporary commentary is provided on rapidly progressing efforts to elucidate the genetic pathogenesis of AMD as the field stands at the end of the first decade of the 21st century.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.